



FEBRUARY EDITION

# The Pharma Focus

*Quarterly*



*Your touchstone for the latest Pharma research*

Welcome to the first 2024 issue of Pearson's quarterly newsletter, *The Pharma Focus!* Our Pharma team is dedicated to curating the most relevant content to help you stay informed about the Pharma research industry. This edition features updates from the Pharma research industry, a featured webinar with our partners at Biopharma Dive, pertinent and timely articles, and research that utilizes many of our own widely used assessments.



KOL SPOTLIGHT

**Finding the Best Metrics for Pediatric Neurogenetic Trials**

*Dr. Elsa Shapiro, Dr. Julie Eisengart, and Dr. Paul Harmatz*

Up to three percent of children suffer from neurogenetic illnesses that influence brain function, but the instruments available for examination are not sensitive enough to identify changes in the developmental skills of these individuals. Researchers and trial sponsors are anxious to see new and improved techniques to test treatments for all pediatric neurogenetic illnesses, as recent data suggests.

Gain more expert insight into the difficulties associated with therapy in these trial settings.

**WATCH ON DEMAND** →

---

## **Let's meet at ISCTM**

Are you exploring optimal protocol outcomes? Let's have a conversation! Lynsey Psimas, PhD, Pearson's Director of Pharma Business Development, is attending ISCTM in Washington, D.C. on February 21-23 and would be delighted to meet you!

Are you also attending ISCTM?

**MEET WITH LYNSEY** →



PHARMA FOCUS FEATURED  
ARTICLES

*See how our clinical outcome assessments (COAs) are being used in the field.*

## **The relationship between physical function and psychological symptoms in Parkinson's disease: A systematic review and meta-regression analysis**

The purpose of this systematic review and meta-regression was to look at the available research on measures of physical function, anxiety, and/or depression in

people with Parkinson's disease to see if there were any correlations between these measurements. Meta-regressions of five combinations of paired physical and psychological outcomes revealed a significant moderating effect of depression symptoms on mobility. This study features the Beck Anxiety Inventory<sup>®</sup> (BDI<sup>®</sup>).

**READ THE ARTICLE** →

---

## **Adaptive behavior assessed by Vineland-3 as comprehensive outcome measure in vanishing white matter**

Leukodystrophy vanishing white matter (VWM) is an uncommon, hereditary neurodegenerative illness defined by gradual white matter loss. VWM leads to severe neurological impairment and premature death. This study investigates results and usability of the Vineland-3 as an effective outcome measure for exploring and quantifying complex cognitive, behavioral, and psychiatric impairments affecting daily functioning in patients with VWM.


**READ THE ARTICLE** →

---

## **Predictive Model of Anxiety and Depression Perception in Multiple Sclerosis Patients: Possible Implications for Clinical Treatment**

The neurological illness known as Multiple Sclerosis (MS) causes both motor and non-motor symptoms including emotional distress, anxiety, and depression. These emotional symptoms have limited pharmacological treatment, making it vital to investigate their link with other psychological, functional, or prefrontal changes. Furthermore, it is critical to investigate non-pharmacological therapy approaches found to aid MS patients in terms of emotional distress management. A descriptive, observational, and cross-sectional study was performed with a sample of 64 diagnosed MS patients who completed functional and cognitive testing using numerous questionnaires and scales, including the Beck Depression Inventory (BDI-II).

[READ THE ARTICLE →](#)



PUBLISHED RESEARCH

## The Pharma research page

Visit the Pharma Research page to discover a curated list of peer-reviewed publications spanning several clinical areas in the pharma industry, Growth Scale Value (GSVs) Reports, and the latest Pharma blog posts.

*All featured research is open access, so any articles you select are available to read, download, and share.*

[VIEW THE RESEARCH PAGE →](#)



THE LATEST

## Welcome Katrina Bengtson!

This year, the Pharma Team welcomed Katrina to our account manager team. Katrina joins the Pearson Pharma team with a background as both a psychometrist and clinical trial management. Prior to joining Pearson, Katrina worked in pharmaceutical clinical operations specializing in study start-up at a Clinical Research Organization (CRO). Katrina gained familiarity with Pearson Assessments from her time as



a Psychometrist conducting neurocognitive evaluations  
at the Anschutz Medical Campus in Colorado.



## MEET OUR TEAM

### How can our team support you?

For more than 80 years, Pearson has been at the forefront of developing the leading clinical and educational assessments that are used in many of today's research projects.

We've continued building on each decade of experience and user feedback, and as a result, today's robust COA portfolio includes **reliable**, **valid**, and **sensitive tools** used by global pharmaceutical companies, biotech companies, and contract research organizations (CROs) conducting clinical research.



**Lynsey Psimas, PhD**  
*Director of Pharma Sales*



**Paul Williams, PsyD**  
*Senior Account Manager*



**Jarett Lehner**  
*Account Manager*

[Reach out to our Pharma team](#) to start the conversation.



800-627-7271 | [PearsonAssessments.com](https://www.PearsonAssessments.com)

Forward to a friend

C7445 SR 2/24